Hillstar Bio closes $67 million Series A financing round
Date
March 25, 2025
Location
London
“Congratulations to US-based Hillstar Bio on closing a $67 million Series A financing round, which LifeArc Ventures supported alongside international investors including Droia Ventures, Frazier Life Sciences and Novo Holdings. We’re impressed by Hillstar Bio’s first-rate leadership and scientists, who are driving an innovative approach to treating autoimmune diseases, and we look forward to their lead programme moving into clinical trials next year with an initial focus on axial spondyloarthritis.”
Sohaib Mir, Partner, LifeArc Ventures.
